Fatty Liver Treatment Market Demonstrates Long-Term Growth Potential At 7.5% CAGR

An in-depth look at the fatty liver treatment sector reveals a promising future driven by medical advancements and growing healthcare needs. As awareness of liver health increases globally, the market is set to experience substantial growth supported by innovative therapies and evolving diagnostic methods. This overview explores the market's expected valuation, key players, prevailing trends, and significant segments shaping the industry's landscape.

Projected Expansion of the Fatty Liver Treatment Market by 2030
The fatty liver treatment market is anticipated to see robust expansion, reaching a value of $35.67 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this surge include the introduction of new drugs targeting non-alcoholic fatty liver disease (NAFLD), a rise in the adoption of non-invasive diagnostic techniques, increasing focus on preventive healthcare practices, broader availability of tele-hepatology services, and escalating investments dedicated to liver disease research. Key trends set to define this period comprise the increasing prevalence of NAFLD, greater emphasis on lifestyle-driven treatment strategies, enhanced use of precision-targeted drug therapies, expansion of early liver disease screening programs, and the incorporation of digital health technologies for ongoing disease management.

The fatty liver treatment market size has grown strongly in recent years. It will grow from $25.05 billion in 2025 to $26.75 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increase in obesity rates, rising diabetes prevalence, improved liver diagnostic tools, growing awareness of liver health, expansion of hepatology clinics.

Download a free sample of the fatty liver treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Leading Corporations Influencing the Fatty Liver Treatment Market
Several major pharmaceutical and biotechnology companies dominate the fatty liver treatment arena, including Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., and Alnylam Pharmaceuticals Inc.
In a notable move from March 2023, Ipsen, a French biopharma company, acquired Albireo Pharma Inc. for $952 million. This acquisition significantly bolstered Ipsen's focus on rare diseases, enhancing its pipeline with promising therapies targeting uncommon cholestatic liver conditions affecting both pediatric and adult populations. Albireo, a US-based biotech firm, specializes in developing bile acid modulators designed for treating fatty liver disorders, thereby strengthening Ipsen's portfolio in rare disease treatment.

Emerging Innovations Defining the Fatty Liver Treatment Industry
The fatty liver treatment market is witnessing a shift toward novel therapeutic approaches, particularly with the development of next-generation metabolic-modulating biologics. These advanced therapies target fundamental metabolic and inflammatory pathways involved in NAFLD and nonalcoholic steatohepatitis (NASH), offering a more precise and disease-altering alternative to conventional lifestyle modifications, which often yield limited results for severe cases.
For example, in March 2023, Akero Therapeutics, a biotechnology company based in the United States, announced positive Phase II clinical trial results for efruxifermin. This drug, designed for non-invasively diagnosed NAFLD and NASH patients, is a unique Fc-FGF21 fusion protein that replicates the biological actions of fibroblast growth factor 21 (FGF21). FGF21 plays a critical role in regulating multiple metabolic routes and cellular processes, making efruxifermin a promising candidate in targeted fatty liver disease therapy.

View the full fatty liver treatment market report:
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Core Segments and Subcategories Within the Fatty Liver Treatment Market
This report divides the fatty liver treatment market into several key segments:
1) Treatment Type:
- Anti-Viral Drugs
- Chemotherapy Drugs
- Targeted Therapy
- Anti-Fibrotic Drugs
2) Disease Type:
- Hepatitis
- Liver Cancer
- Non-Alcoholic Fatty Liver Disease
- Other Diseases
3) End User:
- Hospitals
- Ambulatory Surgery Centers
- Other End Users
Further breakdowns include:
- Anti-Viral Drugs: Direct-Acting Antivirals (DAAs) and Nucleos(t)ide Analogs
- Chemotherapy Drugs: Conventional Chemotherapy Agents alongside novel agents under investigation
- Targeted Therapy: Small Molecule Inhibitors and Monoclonal Antibodies
- Anti-Fibrotic Drugs: PPAR Agonists, FXR Agonists, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and other insulin sensitizers

This structure highlights the diversity of treatment options and specialized approaches being developed to confront the complexities of fatty liver diseases effectively.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.